Reported 1 day ago
Novo Nordisk is experiencing a surge in prescriptions for its weight loss drug Wegovy following a US ban on copycat versions. New prescriptions have risen by 33%, but investors and analysts are pressuring the company to demonstrate sustained growth ahead of its upcoming earnings report. Despite recent positive trends, sentiment remains weak, partly due to recent executive changes and competition from Eli Lilly's Zepbound. Analysts are cautious but see potential for long-term growth if Novo can effectively reclaim patients from the compounded drug market.
Source: YAHOO